Viela Bio, Inc.

The United States of America, As Represented by the Secretary, Department of Health and Human Services

Horizon Therapeutics Ireland Dac

Bo Chen

Katherine Ann Vousden

Gary Patrick Sims

Yien Che Tsai

Allan M Weissman

Jennifer Mariano

The disclosure provides FcγRIIA-binding molecules, for example, humanized monoclonal antibodies capable of inhibiting FcγRIIA activity, and methods of using the FcγRIIA binding molecules, for example, in treating or preventing inflammatory, immune-mediated, or autoimmune diseases or disorders.

Binding molecules specific for fcγRIIA and uses thereof

The disclosure provides Fc&#x3b3;RIIA-binding molecules, for example, humanized monoclonal antibodies capable of inhibiting Fc&#x3b3;RIIA activity, and methods of using the Fc&#x3b3;RIIA binding molecules, for example, in treating or preventing inflammatory, immune-mediated, or autoimmune diseases or disorders.

Binding molecules specific for Fc&#x3b3;RIIA and uses thereof

The present invention features isolated nucleic acid molecules, designated G2BD nucleic acid molecules, which encode the binding site from the gp78 ubiquitin ligase that binds to the Ube2G2 ubiquitin conjugating enzyme. The invention further provides isolated G2BD proteins and fusion proteins. Still further provided are diagnostic and therapeutic methods, as well as screening assays utilizing compositions of the invention.

Ube2G2 binding domain in the ubiquitin ligase gp78 and methods of use thereof

Growing community of inventors

Frederick, MD, United States of America

Bo Chen